2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.11A.11 Application of Circulating Tumor Cell (CTC) PD-L1 Detection in the Evaluation of Therapeutic Efficacy in Advanced NSCLC: A Retrospective Study

EP.11A.11 Application of Circulating Tumor Cell (CTC) PD-L1 Detection in the Evaluation of Therapeutic Efficacy in Advanced NSCLC: A Retrospective Study

Back to course

Pdf Summary

This retrospective study, conducted at the National Cancer Center in Shenzhen, China, explores the use of circulating tumor cell (CTC) PD-L1 detection in evaluating the therapeutic efficacy of immunotherapy in advanced non-small cell lung cancer (NSCLC). Given the challenges and risks associated with tissue biopsy for monitoring PD-L1 expression due to intratumoral heterogeneity, this study aims to assess the consistency between CTC-derived PD-L1 and traditional tissue PD-L1 analysis, as well as the potential of CTC PD-L1 as a predictive marker for treatment response and prognosis.<br /><br />The study involved 64 patients newly diagnosed with advanced NSCLC, who underwent PD-L1 detection using immunohistochemistry. CTCs were captured from patients’ blood using a microfluidic chip-based CTC screening platform. PD-L1 expression was dynamically evaluated at critical treatment stages.<br /><br />Results showed that CTCs were detected in 89% of patients at baseline, and PD-L1 positive CTCs were found in 44 of these 57 patients (77.2%). There was a 70.2% overall concordance between PD-L1 status in tissue samples and CTCs, indicating high consistency. Additionally, patients with high baseline levels of CTCs had lower disease control rates, whereas the response to immunotherapy for patients with CTC PD-L1 positive expression was no less effective than for those with tissue PD-L1 positive expression.<br /><br />These findings suggest that CTC PD-L1 detection is consistent with tissue PD-L1 detection and could serve as an alternative approach for making therapy decisions. Serial CTC biopsies may offer a viable method for monitoring treatment responses in immunotherapy, providing valuable data that can aid in clinical decision-making for NSCLC patients.

Asset Subtitle

Youjun Deng

Meta Tag

Speaker Youjun Deng

Topic Metastatic Non-small Cell Lung Cancer – Immunotherapy

Keywords

circulating tumor cells

PD-L1 detection

immunotherapy

non-small cell lung cancer

NSCLC

biopsy

prognosis

treatment response

clinical decision-making

retrospective study